1 November 2020 in International Journal of Radiation Oncology, Biology, Physics
16 October 2026 in Journal of Pediatric Surgery
Pediatric patients who experience firearm injury may be at risk for subsequent reinjury, yet the timing and predictors of recurrence remain poorly defined. Characterizing reinjury patterns at both individual and system levels is essential for informing targeted prevention strategies. We performed a retrospective review (2010-2024) of patients aged 0-18 years presenting with non-self-inflicted firearm injuries to two Level I pediatric and adult trauma centers. Cross-institutional database linkage was used to identify reinjury events. Cumulative incidence functions estimated reinjury risk over time, accounting for death as a competing risk. Univariate and multivariate Cox proportional hazards models evaluated independent predictors of reinjury. Among 834 patients (84.9% male, 79% Black; median age 17 years [IQR 15-18]), 67 died from their index injury and 75 sustained a subsequent firearm injury at a median of 22 months (IQR 12-61). No reinjury events occurred among children younger than 11 years. Cumulative reinjury incidence at one, three, and five years was 2.5% (1.4-3.6), 5.9% (4.2-7.5), and 7.8% (5.8-9.7), respectively. Assault-related index injury (aHR 2.18, 95% CI 1.10-4.35), lower injury severity (aHR 0.59, 95% CI 0.36-0.97), and treatment at an adult trauma center (aHR 3.43, 95% CI 1.46-8.06) were independently associated with increased reinjury risk. Firearm reinjury among pediatric patients is concentrated in adolescence and often occurs years after the initial event. Reinjured youth were more likely to have been assaulted, uninsured, and initially treated for relatively minor injuries-factors that may limit engagement with supportive services. These findings underscore the need for developmentally tailored violence-prevention and resource-linkage interventions initiated at the time of first injury.
1 January 2025 in Case Reports in Genetics
Dep domain‐containing Protein 5 (DEPDC5), encoded by the gene DEPDC5, regulates the cell cycle by inhibiting the mTORC1 pathway in response to amino acid deficiency. Loss of function DEPDC5 variants are recognized to present as focal familial epilepsy; however, associations with comorbid brain malformations and neurodevelopmental disorders have also been reported. mTOR inhibitors were found to benefit DEPDC5‐knockout mice. Fragile X syndrome (FXS) is an X‐linked neurodevelopmental disorder caused by loss of function of FMR1, and females are expected to have milder neurodevelopmental presentations than males. The reported individual is a 17‐year‐old female diagnosed with FXS at 1 year of age, but the severity of her neuropsychiatric symptoms prompted further genetic testing at age 14, revealing a likely pathogenic c.4307_4310del DEPDC5 variant. Following this diagnosis, she was started on the mTOR inhibitor sirolimus without significant clinical response. She has never been diagnosed with epilepsy; however, her DEPDC5 and FXS dual diagnosis was thought explanatory for her presentation. A review of 213 previously reported individuals with DEPDC5‐related disorder demonstrated that 15.2% of individuals do not have epilepsy, 24.3% have intellectual disability, and 33.8% have brain malformations. Her lack of response to sirolimus may represent the presence of a critical treatment window for mTOR inhibitors in neurodevelopmental disorders.